DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Sweden
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
BIOG B logo

BioGaia AB (publ) Stock Price

OM:BIOG B Community·SEK 11.1b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 26 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

BIOG B Share Price Performance

SEK 110.00
-0.30 (-0.27%)
​
SEK 152.50
Fair Value
SEK 110.00
-0.30 (-0.27%)
27.9% undervalued intrinsic discount
SEK 152.50
Fair Value
Price SEK 110.00
AnalystConsensusTarget SEK 152.50
Tue, 21 Jul 26
Fair ValueSEK 152.50
Share Pricen/a

BIOG B Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value SEK 152.5 27.9% undervalued intrinsic discount

Expanding North American Demand Will Unlock New Health Trends

0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
BIOG B logo
BioGaia
27.9% undervalued intrinsic discount

Expanding North American Demand Will Unlock New Health Trends

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 21 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
BIOG B logo

BIOG B: Dividend Power And Skincare Expansion Will Support Future Rerating

Fair Value: SEK 152.5 27.9% undervalued intrinsic discount
16 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Outstanding track record with flawless balance sheet.

1 Risk
3 Rewards
View Full Analysis

BioGaia AB (publ) Key Details

SEK 1.6b

Revenue

SEK 426.6m

Cost of Revenue

SEK 1.2b

Gross Profit

SEK 806.8m

Other Expenses

SEK 347.2m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Feb 12, 2027
3.43
73.01%
21.97%
0%
View Full Analysis

About BIOG B

Founded
1990
Employees
251
CEO
Theresa Agnew
WebsiteView website
www.biogaiagroup.com

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee’s dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.

Recent BIOG B News & Updates

User avatar
Narrative Update • Jul 21

BIOG B: Dividend Power And Skincare Expansion Will Support Future Rerating

Analysts have trimmed their price target on BioGaia to SEK 152.50 from SEK 165.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News BioGaia New Sciences AB expanded the BioGaia Skincare portfolio with two new products, Gentle Balm to Milk Wash and Soothing Face & Body Lotion, and introduced an updated design across the full range, targeting babies and children with dry, sensitive and atopic prone skin.

Recent updates

No updates

BioGaia AB (publ) Competitors

SOBI logo

Swedish Orphan Biovitrum

Symbol: OM:SOBI
Market cap: SEK 155.6b
CAMX logo

Camurus

Symbol: OM:CAMX
Market cap: SEK 35.9b
BIOA B logo

BioArctic

Symbol: OM:BIOA B
Market cap: SEK 28.5b
ALIF B logo

AddLife

Symbol: OM:ALIF B
Market cap: SEK 19.8b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide